Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 4/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251929 | 0.84 | MEP1B (0.52) | FOLH1MEP1BMMP2HPGDSMMP12 | |
| SCHEMBL2246569 | 0.84 | FOLH1 (0.53) | FOLH1MEP1BMMP2CYP1A2CYP2D6 | |
| SCHEMBL2247649 | 0.84 | FOLH1 (0.56) | FOLH1MEP1BHPGDS | |
| SCHEMBL2249535 | 0.84 | MEP1B (0.54) | MEP1BMMP2HPGDSMMP12MMP8 | |
| SCHEMBL2252834 | 0.83 | FOLH1 (0.52) | FOLH1MEP1BMMP2HPGDSMMP12 | |
| SCHEMBL2250379 | 0.81 | FFAR1 (0.54) | MEP1B | |
| SCHEMBL2248272 | 0.81 | MEN1 (0.51) | MEP1BMMP13CYP1A2 | |
| SCHEMBL2247043 | 0.80 | CYP2D6 (0.54) | MEP1BCYP2D6CYP2C19 | |
| SCHEMBL2245669 | 0.78 | MAPK14 (0.49) | MEP1B | |
| SCHEMBL2242288 | 0.77 | FFAR1 (0.51) | FOLH1MEP1BMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | FOLH1 17/4885MEP1B 2803/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | FOLH1 17/4885MEP1B 2803/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.